D.E. Shaw & Co
SMMT icon

D.E. Shaw & Co’s Summit Therapeutics SMMT Stock Holding History

D.E. Shaw & Co’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,000
Closed -$981K – 4706
2024
Q4 		$981K Buy
+55,000
New +$1.07M ﹤0.01% 3215

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's SMMT Position: Q1 2026 in Review

D.E. Shaw & Co increased its Summit Therapeutics (SMMT) stake by 440% in Q1 2026, buying an estimated $29.5M and bringing the position to 2,242,229 shares worth $42.5M. The position accounts for 0.03% of the portfolio, ranked #726.

D.E. Shaw & Co first reported a position in SMMT in Q2 2021 and has held it in 11 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • D.E. Shaw & Co held 2,242,229 shares of Summit Therapeutics worth $42.5M as of Q1 2026.
  • D.E. Shaw & Co bought 1,826,945 Summit Therapeutics shares in Q1 2026, an estimated $29.5M.
  • Summit Therapeutics made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #726 holding.
  • D.E. Shaw & Co first reported a position in Summit Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.